GLP-1 RAs Associated With Reduced Progression in Some Cancers

In one of the most significant recent developments in metabolic health, a study found that GLP-1 receptor agonists (GLP-1 RAs) are associated with a significant reduction in the metastatic progression of four solid tumors. These findings suggest that the promise of GLP-1 RAs may extend well beyond the management of type 2 diabetes and obesity.

GLP-1 RAs are known as “pleiotropic” drugs. Their expansion from a therapy originally developed for type 2 diabetes to a now far more famous role as a weight-loss adjunct is a striking case study in the incidental discovery of unexpected clinical benefits from a relatively well-established drug class.

As obesity figures climb and healthcare costs rise, public health bodies are increasingly contemplating the role GLP-1 RAs may play in alleviating the global obesity epidemic. Excess adiposity increases the risk of comorbidities, which raises healthcare resource utilization, which at some point may become unsustainable. In countries such as the UK, where the government funds the majority of healthcare, the rising trend of obesity foreshadows heavy costs for a system already under strain.

For the last few years, conversations around GLP-1 RAs have centered on accessibility and affordability. This new study on their potential role in oncology suggests their impact on public health may be even more substantial than previously envisioned.

The study

Orland and colleagues noted that emerging data suggest GLP-1 RAs have immunomodulatory effects, and they sought to assess their potential impact on cancer progression. The team accessed data from the TriNetX Global Health Research Network and identified 10,225 patients who began GLP-1 RA use after being diagnosed with stage I to III cancer.

The researchers focused on seven cancers: breast adenocarcinoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic adenocarcinoma, hepatocellular carcinoma (HCC), colorectal adenocarcinoma (CRC), and prostate adenocarcinoma. They then propensity-matched patients 1:1 with DPP-4 inhibitor controls, matching for factors such as demographics, smoking history, comorbidities, body mass index, and treatment history.

What they found

GLP-1 RA exposure was associated with decreased metastatic progression, crossing the threshold of statistical significance in NSCLC, breast adenocarcinoma, CRC, and HCC. In addition, high tumor GLP-1R expression was associated with improved survival across the seven cancers, most notably in breast adenocarcinoma. No new safety signals or rise in adverse events were recorded.

The study is significant because it opens an entirely new front in GLP-1 RA research. What is needed now, as Orland and colleagues wrote, is “validation in prospective randomized controlled trials and mechanistic investigation of potential antineoplastic pathways driven by GLP-1 RAs.” It is worth noting that this was a retrospective, propensity-matched database analysis, so it shows association rather than causation.

Medicine moves fast. To keep up with the latest evidence-driven clinical guidelines and recommendations, try Vera Health today. It is completely free.

Reference

Orland MD, Mandala A, Unlu S, et al. Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. J Clin Oncol. 2026;44(16_suppl):3143. doi:10.1200/JCO.2026.44.16_suppl.3143